Breathe Well Live Well
Lung Disease News |
Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma
Lung Disease News Australia-based pharmaceutical company Invion Ltd. recently signed a partnership agreement with Hovione Scientia Ltd., a multinational pharmaceutical company focused on developing inhaled therapeutics, for the advancement of INV104 (zafirlukast) as a … |
View full post on asthma – Google News
|
Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma Lung …
Lung Disease News GSK Expands Its COPD And Asthma Portfolio Across The US. Australia-based pharmaceutical company Invion Ltd. recently signed a partnership agreement with Hovione Scientia Ltd., a multinational pharmaceutical company focused on developing inhaled … |
View full post on asthma – Google News
|
Invion repurposes blood pressure drug to target asthma
Australian Life Scientist Invion repurposes blood pressure drug to target asthma. Nadolol is known for its role in treating blood pressure, but now Invion is conducting a phase II trial to assess its effects on asthma and chronic bronchitis. Tim Dean (Australian Life Scientist … |
View full post on asthma – Google News
|
INVION LTD : Invion announces initiation of phase II asthma study
4-traders Invion Limited (ASX:IVX), a clinical-stage drug development company targeting chronic inflammation, today announced the initiation of "NIMA", a phase II clinical trial that is funded by the US National Institute of Allergy and Infectious Diseases … |
View full post on asthma – Google News
 MENAFN.COM |
Invion starts second phase trial for asthma treatment
MENAFN.COM (MENAFN – ProactiveInvestors – Australia) Invion (ASX: IVX) has initiated the phase II "NIMA" clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and … |
View full post on asthma – Google News
 Proactive Investors Australia |
Invion starts second phase trial for asthma treatment
Proactive Investors Australia Invion (ASX: IVX) has initiated the phase II “NIMA” clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative … |
View full post on asthma – Google News